Key facts
- This page summarizes Gary A. Lyons's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jul 2024, 16:54.
Gary A. Lyons - 16 Jul 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Director
- Issuer ticker
- NBIX
- Reported as of
- 16 Jul 2024
- Net transaction value
- -$99,763
- SEC form
- 4
- Accepted by SEC
- 18 Jul 2024, 16:54:02 UTC
- Prior SEC filing
- 23 May 2024
- Next SEC filing
- 15 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gary A. Lyons filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 18 Jul 2024.
Change
- Previous filing in this sequence was filed on 23 May 2024.
- Current net transaction value: -$99,763.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $39,767
- Shares
- +930
- Change %
- +0.78%
- Price
- $42.76
- Shares after
- 119,977
- Date
- 16 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
NBIX
transaction
Common Stock
Sale
- Transaction value
- $139,530
- Shares
- -930
- Change %
- -0.78%
- Price
- $150.03
- Shares after
- 119,047
- Date
- 16 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Non-Qualified Stock Option
Options Exercise
- Transaction value
- $0
- Shares
- -930
- Change %
- -7.4%
- Price
- $0.000000
- Shares after
- 11,570
- Date
- 16 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 930
- Exercise price
- $42.76
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
Footnote F2
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024
Footnote F3
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F4
The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.